Mateusz Gawin

Dr. Mateusz Gawin

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MGMateusz Gawin
Mateusz Gawin
EKEmilia Koziara
Emilia Koziara
MGMateusz Gadzina
Mateusz Gadzina
JGJulia Gawlak
Julia Gawlak
MKMaciej Krzesimir Kuświk
Maciej Krzesimir Kuświk
AGAleksandra Golec
Aleksandra Golec
Major depressive disorder (MDD) is one of the leading causes of disability worldwide. A substantial proportion of patients fail to achieve remission through standard monoaminergic therapies, meeting the clinical criteria for treatment-resistant depression (TRD). TRD is associated with significant clinical morbidity and a profound economic burden on healthcare systems. This review evaluates the clinical efficacy, safety profile, and neurobiological mechanisms of psilocybin, a serotonergic psychedelic, as a targeted intervention for TRD. Current neurobiological evidence indicates that psilocybin, upon conversion to its active metabolite psilocin, acts primarily as a 5-HT2A receptor agonist. This mechanism promotes rapid structural neuroplasticity and modulates the aberrant functional connectivity characteristic of severe depression. Recent randomized clinical trials demonstrate that psilocybin, when administered in controlled settings with psychological support, produces rapid and clinically significant reductions in depressive symptoms. Comparative data indicate that its therapeutic efficacy is at least comparable to standard first-line treatments, such as SSRIs, while frequently offering a faster onset of action. Regarding safety, psilocybin is generally well-tolerated in clinical environments; adverse events are typically mild to moderate and transient. However, the strict requirement for concurrent psychological support and rigorous psychiatric screening highlights a clinical complexity distinct from traditional pharmacotherapies. Overall, current evidence indicates that psilocybin is a promising intervention for TRD with a manageable safety profile in controlled settings. Nevertheless, large-scale, long-term randomized trials are required to determine the durability of its effects and to establish standardized treatment protocols.

7 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ZTZofia Tarnawska
Zofia Tarnawska
KFKarolina Figiel
Karolina Figiel
MKMaciej Krzesimir Kuświk
Maciej Krzesimir Kuświk
MZMateusz Zawisza
Mateusz Zawisza
WSWojciech Sontag
Wojciech Sontag
AGAleksandra Golec
Aleksandra Golec
Porphyrias are a group of metabolic diseases caused by an impairment of the heme synthesis pathway, resulting in the accumulation of heme precursors. First symptoms usually occur during puberty and can be triggered by a range of factors such as drugs, alcohol, fasting, infection, and, most importantly for this study, hormonal changes. Women in the reproductive age are known to be the main group presenting with porphyria symptoms (1.5–2.5 times more frequent in women than in men) mainly due to higher concentrations of steroid hormones, particularly progesterone. Hormonal fluctuations associated with the menstrual cycle are the most commonly identified trigger causing an AIP attack in female patients. Pregnancy and exogenous hormone administration may also precipitate attacks in susceptible individuals, although there is considerable interindividual variability, and the underlying mechanisms remain incompletely understood. This review summarizes existing knowledge on hormonal changes induced by the menstrual cycle, pregnancy, hormonal contraception, and GnRH agonists in women diagnosed with porphyria. It compares it with the conclusions reached by the IPNET panelists in the newly published guidelines, released in May 2026. The available evidence, derived mainly from retrospective studies, small cohorts, and case reports, indicates that endogenous and exogenous hormones can have a major impact on susceptible women with porphyria. Most data confirmed that the use of oral contraceptives appears to carry the highest risk of precipitating attacks, whereas levonorgestrel-releasing IUDs seem to be better tolerated. GnRH agonist therapy proved highly effective and significantly safer than hormonal contraception in the treatment of recurrent cycle-related porphyria, although it requires add-back therapy, posing a threat itself. Despite recent advances and the publication of IPNET recommendations, high-quality evidence remains limited. Further prospective studies are required to establish evidence-based recommendations for hormonal management and contraception in women with acute hepatic porphyrias.

18 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MKMaciej Krzesimir Kuświk
Maciej Krzesimir Kuświk
WSWojciech Sontag
Wojciech Sontag
JGJulia Gawlak
Julia Gawlak
ZTZofia Tarnawska
Zofia Tarnawska
KFKarolina Figiel
Karolina Figiel
AGAleksandra Golec
Aleksandra Golec
Acute kidney injury (AKI) is a common clinical syndrome associated with increased morbidity, mortality, length of hospitalization, and long-term risk of chronic kidney disease. In routine practice, AKI is still diagnosed primarily by changes in serum creatinine concentration and urine output. Although these criteria are standardized and clinically useful, they are imperfect markers of early kidney injury because creatinine rises only after a fall in filtration has occurred and urine output is influenced by hemodynamics, medications, fluid balance, and measurement accuracy. This systematic literature review evaluates the role of emerging biomarkers in the early detection and risk stratification of AKI in adults, with particular emphasis on neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), liver-type fatty acid-binding protein (L-FABP), cystatin C, and the cell-cycle arrest biomarker combination tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7 ([TIMP-2]*[IGFBP7]). The reviewed literature suggests that biomarkers may identify tubular stress or injury earlier than conventional criteria, support risk stratification in selected high-risk populations, and help distinguish functional decline from structural damage. However, heterogeneity of populations, assay platforms, timing of sampling, thresholds, and reference standards limits routine implementation. Biomarkers are best understood as adjuncts to clinical assessment rather than replacements for standard diagnostic criteria.

7 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
EKEmilia Koziara
Emilia Koziara
MGMateusz Gadzina
Mateusz Gadzina
WSWojciech Sontag
Wojciech Sontag
JGJulia Gawlak
Julia Gawlak
ZTZofia Tarnawska
Zofia Tarnawska
MKMaciej Krzesimir Kuswik
Maciej Krzesimir Kuswik
Obesity and asthma are common chronic conditions that frequently coexist in adults and contribute to a substantial clinical and public health burden. Although excess body weight affects asthma through mechanical effects on lung volumes and airway closure, current evidence increasingly supports the role of obesity-related chronic low-grade inflammation as a central mechanism linking obesity with asthma development, severity, symptom burden, exacerbation risk, and therapeutic response. This systematic review summarizes contemporary evidence on the role of adipose-tissue inflammation, adipokines, cytokine signaling, metabolic dysfunction, oxidative stress, and immune dysregulation in the pathogenesis and clinical expression of obesity-related asthma in adults. A structured literature search was performed using major biomedical databases, with priority given to systematic reviews, meta-analyses, clinical reviews, cohort studies, mechanistic studies, and current asthma guidelines. The available literature indicates that obesity-related asthma is not a single uniform phenotype but a heterogeneous clinical entity involving overlapping inflammatory, metabolic, mechanical, and behavioral pathways. Increased systemic inflammatory activity, altered leptin and adiponectin signaling, elevated interleukin-6, neutrophilic airway inflammation, insulin resistance, and comorbidities such as obstructive sleep apnea and gastroesophageal reflux may all contribute to worse asthma control. Clinical management should therefore extend beyond inhaled pharmacotherapy and include assessment of obesity as a treatable trait, weight management, comorbidity screening, lifestyle intervention, and individualized evaluation of inflammatory phenotype. Future studies should clarify causal mechanisms and determine which interventions most effectively improve asthma outcomes in adults with obesity.

31 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
WSWojciech Sontag
Wojciech Sontag
AGAleksandra Golec
Aleksandra Golec
MZMateusz Zawisza
Mateusz Zawisza
MGMateusz Gadzina
Mateusz Gadzina
EKEmilia Koziara
Emilia Koziara
MKMaciej Krzesimir Kuświk
Maciej Krzesimir Kuświk
Obesity and obstructive sleep apnea (OSA) are common, clinically important and mutually reinforcing conditions associated with metabolic, cardiovascular and respiratory morbidity. Although obesity is widely recognized as a major modifiable risk factor for OSA, the relationship between sleep, weight regulation and sleep-disordered breathing is not limited to mechanical narrowing of the upper airway. The aim of this systematic review was to synthesize current evidence on the role of sleep duration, sleep quality, circadian disruption and sleep fragmentation in the pathogenesis of obesity and adult OSA. Scientific publications indexed in PubMed were reviewed, with priority given to systematic reviews, meta-analyses, prospective cohort studies, randomized controlled trials and major clinical reviews. The evidence indicates that short sleep duration is associated with future obesity and central obesity, while experimental sleep restriction promotes increased energy intake, impaired insulin sensitivity and adverse metabolic changes. Obesity contributes to OSA through upper-airway soft tissue enlargement, reduced lung volumes, increased pharyngeal collapsibility and altered ventilatory control. Conversely, OSA may worsen metabolic dysfunction through intermittent hypoxia, sleep fragmentation, sympathetic activation, oxidative stress and inflammation. These findings support a bidirectional model in which insufficient sleep, obesity and OSA interact through behavioral, endocrine, inflammatory and respiratory mechanisms. Adult patients with obesity should therefore be routinely assessed for sleep health and OSA risk, while OSA management should include weight and metabolic strategies in addition to airway-directed therapy.

7 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MZMateusz Zawisza
Mateusz Zawisza
WSWojciech Sontag
Wojciech Sontag
JGJulia Gawlak
Julia Gawlak
ZTZofia Tarnawska
Zofia Tarnawska
KFKarolina Figiel
Karolina Figiel
MKMaciej Krzesimir Kuświk
Maciej Krzesimir Kuświk
Objective: To synthesize current evidence on the diagnosis, prevention, pharmacological treatment, and long-term management of osteoporosis in adults. Methods: PubMed/MEDLINE and reference lists of major guidelines, position statements, systematic reviews, meta-analyses, and pivotal randomized trials were searched, with emphasis on evidence published from 2022 to 2026 and inclusion of older landmark trials when clinically relevant. Findings: Contemporary assessment integrates dual-energy X-ray absorptiometry (DXA) with fracture history, clinical risk factors, FRAX, vertebral imaging, and evaluation for secondary causes. Prevention combines adequate nutrition, correction of vitamin D deficiency, exercise, fall prevention, smoking cessation, and avoidance of excessive alcohol. Bisphosphonates and denosumab remain major antiresorptive therapies, whereas teriparatide, abaloparatide, and romosozumab are important options for selected patients at very high fracture risk. Treatment sequencing and planned antiresorptive therapy after anabolic treatment or denosumab discontinuation are central to long-term care. Conclusions: Osteoporosis management should be individualized according to absolute and imminent fracture risk. The principal therapeutic goal is prevention of fragility fractures and preservation of function rather than improvement in BMD alone.